Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Hodgkin Lymphoma (Volume II)
share announcement

Hodgkin Lymphoma (Volume II)

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".

Deadline for manuscript submissions: 15 September 2024 | Viewed by 1735

Special Issue Editor

Prof. Dr. Sylvia Hartmann

E-Mail Website
Guest Editor
Senckenberg Institute of Pathology, Goethe University, 60590 Frankfurt am Main, Germany
Interests: nodular lymphocyte predominant Hodgkin lymphoma; T-cell/histiocyte rich large B-cell lymphoma; classical Hodgkin lymphoma; T cell lymphoma; genomic aberrations; mutations; chemokines; cell motility
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue is the second edition of the Special Issue “Hodgkin Lymphoma,” available at https://www.mdpi.com/journal/cancers/special_issues/Hodgkin

This Special Issue is dedicated to Hodgkin lymphoma. Almost 190 years after the first description by Thomas Hodgkin, tremendous knowledge about the pathogenesis and treatment of Hodgkin lymphoma has been gained. Still, this tumor remains enigmatic in many aspects. The deregulation of several pathways has been described, though the underlying mechanisms are, in many instances, not fully understood. Therefore, this Special Issue welcomes original papers and reviews that address the molecular biology underlying Hodgkin lymphoma as well as translational studies, with a focus on both tumor and bystander cells, bringing a molecular understanding into clinical context and applied settings. Papers featuring a correlation between pathology and molecular data with respect to Hodgkin lymphoma are of particular interest.

Prof. Dr. Sylvia Hartmann
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • classical Hodgkin lymphoma
  • nodular lymphocyte predominant Hodgkin lymphoma
  • Epstein–Barr virus
  • genomics
  • miRNA
  • proteomics
  • transcriptome
  • NGS
  • epigenetics
  • ctDNA
  • translational studies

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

28 pages, 932 KiB  
Review
Advances in Hodgkin Lymphoma Treatment: From Molecular Biology to Clinical Practice
by Corrado Benevolo Savelli, Matteo Bisio, Luca Legato, Filippo Fasano, Elisa Santambrogio, Maura Nicolosi, Deborah Morra, Carola Boccomini, Roberto Freilone, Barbara Botto and Mattia Novo
Cancers 2024, 16(10), 1830; https://doi.org/10.3390/cancers16101830 - 10 May 2024
Viewed by 573
Abstract
Classical Hodgkin Lymphoma (cHL) is a highly curable disease, but around 20% of patients experience progression or relapse after standard frontline chemotherapy regimens. Salvage regimens followed by autologous stem cell transplants represent the historical treatment approach for these cases. In the last decade, [...] Read more.
Classical Hodgkin Lymphoma (cHL) is a highly curable disease, but around 20% of patients experience progression or relapse after standard frontline chemotherapy regimens. Salvage regimens followed by autologous stem cell transplants represent the historical treatment approach for these cases. In the last decade, with the increasing understanding of cHL biology and tumor microenvironment role in disease course, novel molecules have been introduced in clinical practice, improving outcomes in the relapsed/refractory setting. The anti-CD30 antibody-drug conjugated brentuximab vedotin and PD-1/PD-L1 checkpoint inhibitors represent nowadays curative options for chemorefractory patients, and randomized trials recently demonstrated their efficacy in frontline immune-chemo-combined modalities. Several drugs able to modulate the patients’ T-lymphocytes and NK cell activity are under development, as well as many anti-CD30 chimeric antigen receptor T-cell products. Multiple tumor aberrant epigenetic mechanisms are being investigated as targets for antineoplastic compounds such as histone deacetylase inhibitors and hypomethylating agents. Moreover, JAK2 inhibition combined with anti-PD1 blockade revealed a potential complementary therapeutic pathway in cHL. In this review, we will summarize recent findings on cHL biology and novel treatment options clinically available, as well as promising future perspectives in the field. Full article
(This article belongs to the Special Issue Hodgkin Lymphoma (Volume II))
►▼ Show Figures

Figure 1

17 pages, 1275 KiB  
Review
Pinpointing Functionally Relevant miRNAs in Classical Hodgkin Lymphoma Pathogenesis
by Yujia Pan, Roza Cengiz, Joost Kluiver, Arjan Diepstra and Anke Van den Berg
Cancers 2024, 16(6), 1126; https://doi.org/10.3390/cancers16061126 - 12 Mar 2024
Viewed by 838
Abstract
Classical Hodgkin lymphoma (cHL) is a hematological malignancy of B-cell origin. The tumor cells in cHL are referred to as Hodgkin and Reed–Sternberg (HRS) cells. This review provides an overview of the currently known miRNA–target gene interactions. In addition, we pinpointed other potential [...] Read more.
Classical Hodgkin lymphoma (cHL) is a hematological malignancy of B-cell origin. The tumor cells in cHL are referred to as Hodgkin and Reed–Sternberg (HRS) cells. This review provides an overview of the currently known miRNA–target gene interactions. In addition, we pinpointed other potential regulatory roles of microRNAs (miRNAs) by focusing on genes related to processes relevant for cHL pathogenesis, i.e., loss of B-cell phenotypes, immune evasion, and growth support. A cHL-specific miRNA signature was generated based on the available profiling studies. The interactions relevant for cHL were extracted by comprehensively reviewing the existing studies on validated miRNA–target gene interactions. The miRNAs with potential critical roles included miR-155-5p, miR-148a-3p, miR-181a-5p, miR-200, miR-23a-3p, miR-125a/b, miR-130a-3p, miR-138, and miR-143-3p, which target, amongst others, PU.1, ETS1, HLA-I, PD-L1, and NF-κB component genes. Overall, we provide a comprehensive perspective on the relevant miRNA–target gene interactions which can also serve as a foundation for future functional studies into the specific roles of the selected miRNAs in cHL pathogenesis. Full article
(This article belongs to the Special Issue Hodgkin Lymphoma (Volume II))
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop